Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
07 November 2024 - 12:00AM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will
provide business updates and report its financial results for the
third quarter ended September 30, 2024 on Wednesday, November 13,
2024. The company will host a conference call and webcast at 8:00
a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826
(domestic) or 412-317-0689 (international). A live webcast of the
presentation will be available on the Investors & Media section
of the Mersana website at www.mersana.com, and a replay of the
webcast will be available in the same location following the
conference call for approximately 90 days.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel antibody-drug conjugates (ADCs) and driven by
the knowledge that patients are waiting for new treatment options.
The company has developed proprietary cytotoxic (Dolasynthen) and
immunostimulatory (Immunosynthen) ADC platforms that are generating
a pipeline of wholly-owned and partnered product candidates with
the potential to treat a range of cancers. Its pipeline includes
XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an
Immunosynthen ADC targeting a novel epitope of human epidermal
growth factor receptor 2 (HER2). Mersana routinely posts
information that may be useful to investors on the “Investors &
Media” section of its website at www.mersana.com.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Dec 2023 to Dec 2024